EZETIMIBE AND SIMVASTATIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ezetimibe And Simvastatin, and when can generic versions of Ezetimibe And Simvastatin launch?
Ezetimibe And Simvastatin is a drug marketed by Alkem Labs Ltd, Amneal Pharms Co, Ani Pharms, Aurobindo Pharma Usa, Dr Reddys Labs Sa, Glenmark Pharms Ltd, and Watson Labs Inc. and is included in seven NDAs.
The generic ingredient in EZETIMIBE AND SIMVASTATIN is ezetimibe; simvastatin. There are twenty-four drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ezetimibe; simvastatin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ezetimibe And Simvastatin
A generic version of EZETIMIBE AND SIMVASTATIN was approved as ezetimibe; simvastatin by DR REDDYS LABS SA on April 26th, 2017.
Summary for EZETIMIBE AND SIMVASTATIN
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 7 |
Finished Product Suppliers / Packagers: | 11 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Clinical Trials: | 107 |
Patent Applications: | 234 |
Formulation / Manufacturing: | see details |
DailyMed Link: | EZETIMIBE AND SIMVASTATIN at DailyMed |
Recent Clinical Trials for EZETIMIBE AND SIMVASTATIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
The University of Hong Kong | Phase 4 |
Cairo University | N/A |
Aswan Heart Centre | N/A |
Pharmacology for EZETIMIBE AND SIMVASTATIN
Drug Class | Dietary Cholesterol Absorption Inhibitor HMG-CoA Reductase Inhibitor |
Mechanism of Action | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Physiological Effect | Decreased Cholesterol Absorption |